On late April 07, 2017, Fosun Pharma issued an announcement on the progress of the overseas investment, pursuant to which its wholly owned subsidiary, Ample Up Limited intended to take over the 30% equity interest in Chindex Medical Limited (hereinafter referred to as “CML”) held by Chindex Medical Holdings (BVI) Limited (hereinafter referred to as “CMH”) at a consideration of RMB263,589,343. After the completion of such equity transfer, Fosun Pharma will hold 100% equity interest in CML in aggregate.

In 2010, Fosun Pharma and Chindex International, Inc. established a joint venture, i.e. CML, which is a leading supplier of medical devices and is mainly engaged in the manufacturing and sales of medical devices and consumables. As of the date of the announcement, Fosun Pharma holds 70% equity interest in CML. CML is the distributor of the Da Vinci Surgical System of Intuitive Surgical, Inc. in China, and the “Da Vinci Surgical Robot” well known in China is being sold by CML as an agency.

According to Fosun Pharma, it will be based on CML for further accelerating the synergetic development of the medical device business in terms of R&D, manufacturing, sales, product service as well as investment and M&A.